Real Housewives of Beverly Hills alum Teddi Mellencamp shared more bad news amid her ongoing battle with cancer as doctors found new tumors that are Stage 4.

In a study co-led by the University of Maryland School of Medicine (UMSOM), researchers have identified a "master regulator" ...

It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...

Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian ...

Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider ...

Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in ...

What Happened? Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 94.9% in the afternoon session after the ...

The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ...